Sequoia Sciences is a pioneering pharmaceutical company established in 1999, dedicated to developing innovative medical solutions for bacterial infections and cancers. With a mission to enhance the quality of life for individuals suffering from recurrent and chronic bacterial infections and cancers, the company's research focuses on small molecules for bacterial infections and cancers, as well as vaccines to address and prevent recurring urinary tract infections.
Engaging in active research and development programs, Sequoia Sciences collaborates with various entities such as laboratories, universities, clinical research sites, and private businesses. Leveraging their expertise in microscale structure determination, the company aims to elucidate the structures of natural products, biosynthetic intermediates, and unexpected synthetic products for both academic and industrial partners, thereby advancing the development of effective treatments.
The latest investment of $72.00K in Seed Round was made on 27 July 2020 by St. Louis Arch Angels, signaling confidence in the company's vision and potential. With a firm foothold in Biotechnology and Pharmaceutical industries, Sequoia Sciences continues its pioneering efforts to combat challenging health issues, representing an intriguing opportunity for venture capital participation in the pursuit of a healthier future.
